Zacks Investment Research cut shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) from a hold rating to a sell rating in a research note issued to investors on Thursday, July 13th.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
VYGR has been the subject of a number of other research reports. Wedbush reiterated an outperform rating and set a $36.00 target price on shares of Voyager Therapeutics in a research report on Thursday, March 16th. Stifel Nicolaus reiterated a buy rating and set a $33.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, June 27th. Chardan Capital restated a neutral rating and issued a $13.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, March 16th. Finally, TheStreet cut shares of Voyager Therapeutics from a c- rating to a d+ rating in a research report on Friday, April 21st. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Voyager Therapeutics has a consensus rating of Hold and an average target price of $25.33.
Shares of Voyager Therapeutics (NASDAQ:VYGR) opened at 8.78 on Thursday. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $18.25. The stock’s 50 day moving average price is $9.40 and its 200-day moving average price is $10.71. The stock’s market cap is $235.76 million.
Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, May 9th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.11. The firm had revenue of $1.46 million for the quarter, compared to analyst estimates of $3.70 million. Voyager Therapeutics had a negative return on equity of 35.25% and a negative net margin of 457.45%. On average, analysts predict that Voyager Therapeutics will post ($2.54) earnings per share for the current fiscal year.
WARNING: This article was published by BBNS and is the property of of BBNS. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://baseballnewssource.com/markets/voyager-therapeutics-inc-vygr-downgraded-by-zacks-investment-research-to-sell-updated-updated-updated/1198592.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VYGR. Wells Fargo & Company MN raised its position in Voyager Therapeutics by 114.4% in the first quarter. Wells Fargo & Company MN now owns 83,577 shares of the company’s stock valued at $1,107,000 after buying an additional 44,599 shares during the last quarter. Bessemer Group Inc. raised its position in Voyager Therapeutics by 148.1% in the second quarter. Bessemer Group Inc. now owns 44,828 shares of the company’s stock valued at $402,000 after buying an additional 26,763 shares during the last quarter. Wellington Management Group LLP raised its position in Voyager Therapeutics by 17.4% in the first quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock valued at $1,739,000 after buying an additional 19,450 shares during the last quarter. Fiduciary Trust Co. raised its position in Voyager Therapeutics by 19.1% in the first quarter. Fiduciary Trust Co. now owns 108,561 shares of the company’s stock valued at $1,437,000 after buying an additional 17,386 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of Voyager Therapeutics during the fourth quarter valued at approximately $194,000. 41.34% of the stock is currently owned by institutional investors and hedge funds.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with our FREE daily email newsletter.